SCHEMBL18201815

SCHEMBL18201815

CC(C)(C)OC(=O)N1C2CCC1CN(Cc1ccc(N)nc1)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.48
KCNK3 O14649 6/20 0.47
KCNK9 Q9NPC2 6/20 0.47
HDAC1 Q13547 1/20 0.45
HSD11B1 P28845 1/20 0.43
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
JAK1 P23458 3/20 0.38
PREP P48147 1/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18201922 0.93 GPR119 (0.44) GPR119KCNK3KCNK9HDAC1HSD11B1
SCHEMBL31459048 0.86 GPR119 (0.48) GPR119KCNK3KCNK9HDAC1HSD11B1
SCHEMBL28669882 0.86 GPR119 (0.48) GPR119KCNK3KCNK9HDAC1HSD11B1
SCHEMBL18201818 0.83 KCNK3 (0.45) GPR119KCNK3KCNK9HDAC1JAK1
SCHEMBL18201924 0.83 NAMPT (0.41) GPR119HDAC1GABRPGABRDGABRA1
SCHEMBL29686606 0.83 NAMPT (0.41) GPR119HDAC1GABRPGABRDGABRA1
SCHEMBL18201814 0.82 GPR119 (0.48) GPR119ALOX5APFEN1
SCHEMBL31096201 0.81 KCNK3 (0.48) GPR119KCNK3KCNK9HDAC1HSD11B1
SCHEMBL29736294 0.81 HDAC1 (0.52) GPR119KCNK3KCNK9HDAC1HSD11B1
SCHEMBL2305956 0.81 HDAC1 (0.52) GPR119KCNK3KCNK9HDAC1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288931-B2 CERTAIN PROTEIN KINASE INHIBITOR CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) 2022-07-20 EP disclosed
EP-3288931-B1 CERTAIN PROTEIN KINASE INHIBITOR CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) 2019-11-06 EP disclosed
EP-3288931-B1 CERTAIN PROTEIN KINASE INHIBITOR CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) 2019-11-06 EP disclosed
US-10450316-B2 Certain protein kinase inhibitor Chongqing Fochon Pharmaceutical Co., Ltd. (CN) 2019-10-22 US disclosed
US-10450316-B2 Certain protein kinase inhibitor Chongqing Fochon Pharmaceutical Co., Ltd. (CN) 2019-10-22 US disclosed
US-20180291027-A1 CERTAIN PROTEIN KINASE INHIBITOR FOCHON BIOSCIENCES, LTD. (CN) 2018-10-11 US disclosed
WO-2016173505-A1 CERTAIN PROTEIN KINASE INHIBITOR SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) 2016-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450316-B2 Certain protein kinase inhibitor CDK4, CDK6, CDK2 GPR119 1791/4885KCNK3 4185/4885KCNK9 4049/4885
US-20180291027-A1 CERTAIN PROTEIN KINASE INHIBITOR CDK4, CDK6, CDK2 GPR119 2674/4885KCNK3 4280/4885KCNK9 4119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.